All News
EULAR 2022 – Day 2 Report
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
Read Article
The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al
Dr. Antoni Chan synovialjoints ( View Tweet)
For psoriasis +MSK pain, should we be chasing synovitis/enthesitis on ultrasound?
PsO pts with MSK pain n=79
USS inflamm in 47%
Site-spec correlate only OR 3.1
Even if we act on USS:
PsA Rx is systemic, so overall impression is good enough anyway?
POS0131 #EULAR2022 @RheumNow https://t.co/O3P7J2Rskw
David Liew drdavidliew ( View Tweet)
#EULAR2022 OP0274
Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease:
⭐️9% with RA, 6% with PsA and AS in Western Australia
⭐️Decrease overall since 1985, but recent increase
⭐️Sharp rise of mycotic infections
⭐️No PJP, likely due to ppx
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
BE COMPLETE RCT
Bimekizumab vs. PBO in TNFiIR PsA pts
meets its primary criteria at 16wks w/
-ACR50 43%
-PASI 90 69%
and MDA achieved in 40+% pts
No new safety signal.
@RheumNow #EULAR2022 OP0255 https://t.co/QazYlzDqIc
Aurelie Najm AurelieRheumo ( View Tweet)
Merola et al. IL23i Risankizumab in PsA. Proportion achieving ACR20 week24 by subgroup. Effective across all groups. Similar irrespective of demographics, disease characteristics, concomittent meds, prior bDMARD use. @RheumNow #EULAR2022 POS1032 https://t.co/GAVKFpwCst
Richard Conway RichardPAConway ( View Tweet)
FAP tracer-based PET-CT ☄️ (68Ga-FAPI-04)
⚡️Detects metabolic activity and tissular inflammation
⚡️Correlates with MRI changes in PsA
⚡️Is associated
w/ progression of joint damage
⚡️Is sensitive to change
An exciting new imaging modality!
@RheumNow OP0256 #EULAR2022 https://t.co/16Z1R71YjC
Aurelie Najm AurelieRheumo ( View Tweet)
Risk of haematological malignancy in PsA
Nordic cohorts
*40 events, IR 67/100 000 person-years
*NO difference between PsA bionaive and TNFi treated
BUT *⬆️ in PsA vs. matched controls
*no difference between myeloid and lymphoid malignancies.
OP0257 #EULAR2022 @RheumNow https://t.co/oIojobgDP3
Aurelie Najm AurelieRheumo ( View Tweet)
Swedish study by Lindstrom U et al of over 3000 PsA patients matched with RA comparators showed that the length of time on MTX (PsA 4.5 and RA 4.4 years) before adding or switching to b/tsDMARD was identical in PsA (34%) and matched RA controls (33%) #EULAR2022 @RheumNow POS0073 https://t.co/Dwrz8RVMnh
Dr. Antoni Chan synovialjoints ( View Tweet)
Izokibep Phase 2 in active PsA at Wk 16 results (80mg dose):
⭐️ACR50 52%
⭐️PASI 90 50%
⭐️Resolution of enthesitis LEI 88%
⭐️Safety profile similar to what observed in PsO.
Promising for the enthesitis domain!
@RheumNow OP0258 #EULAR2022 https://t.co/Wm3MvVQzoP
Aurelie Najm AurelieRheumo ( View Tweet)
Real world study of over 6500 patients from a French Health Insurance database by Pina Vegas et al showed higher persistence of IL17i than TNFi for PsA and PsO. IL17i had better persistence than IL12/23 for PsA and no difference for PsO over 3 years #EULAR2022 @RheumNow POS0075 https://t.co/hBI8tgb5Jb
Dr. Antoni Chan synovialjoints ( View Tweet)
Updates in Psoriatic Arthritis at EULAR 2022. Here are the topics I will be highlighting at the conference #psoriaticarthritis #EULAR2022 @RheumNow https://t.co/8Dd29GdUuz
Dr. Antoni Chan synovialjoints ( View Tweet)
WATCH: Can Dermatologists Help Detect Psoriatic Arthritis?
Dr. Robert Chao reviews abstract OP0029 presented at #EULAR2022 in June.
https://t.co/bAuCsVLJV2 https://t.co/BjUckSXIJ3
Links:
Dr. John Cush RheumNow ( View Tweet)
Methotrexate plus leflunomide combination therapy for PsA treatment resulted in greater improvement in disease activity when compared to MTX monotherapy. As expected, MTX+LEF less well tolerated.
@RheumNow #EULAR2022 ABST#0078 https://t.co/Bo64QX3Bf9
Robert B Chao, MD doctorRBC ( View Tweet)
Depression was the most prevalent comorbidity (31%), hypertension (26%) and uveitis the most common EMM (30%) in AS from the PSOAS cohort by @rheum_cat .
Five clusters identified with depression and hypertension groups having higher disease activity #EULAR2022 @RheumNow OP0154 https://t.co/dpqaFD4Qzw
Dr. Antoni Chan synovialjoints ( View Tweet)
Risk factors associated with non-remission/LDA in PsA pts:
Baseline TJC>3, SJC>5
CRP>10
HAQ>0.5
enthesitis/dactylitis
BMI>30
sDMARD use
@RheumNow #EULAR2022 ABST#POS0080
Robert B Chao, MD doctorRBC ( View Tweet)
Sex differences in PsA disease expression and treatment. Treatment efficacy and retention rates lower among female PsA pts initiating first TNFi. Women presented with higher 28 TJC and PRO at baseline as well..
@RheumNow #EULAR2022 ABST#POS0077 https://t.co/yV11kCN2bZ
Robert B Chao, MD doctorRBC ( View Tweet)
Kristensen et al. 52 week results KEEPsAKE 1 RCT risankizumab vs PBO to week 24, then rescue, in csDMARD-IR PsA. ACR20 57% vs 34% (PBO) week 24, week 52 70%/63% ACR20. ACR 50/70 similar differences. PASI even better. @RheumNow #EULAR2022 POS1024 https://t.co/USQsMQ7oxu
Richard Conway RichardPAConway ( View Tweet)
Baseline molecular differences noted in PsA patients who are TNFi naive and incomplete responders. Elevated IL-22 expression may suggest increased involvement of IL-23 pathway in TNF-IR pts. @RheumNow #EULAR2022 ABST#POS0074
Robert B Chao, MD doctorRBC ( View Tweet)
Large French study of over 23k patients with either PsA or PsO showed a longer persistence (time of initiation to discontinuation) in those who took IL-17i vs. TNFi for PsA and PsO pts. IL-17i longer than IL-12/23i in PsA pts.
@RheumNow #EULAR2022 ABST#POS0075 https://t.co/rH1g4fPUYC
Robert B Chao, MD doctorRBC ( View Tweet)
